Viking Therapeutics: Wall Street’s Bullish Bet on a GLP-1 Challenger

As U.S. markets operated on a shortened post-Thanksgiving schedule, research departments remained active, with Viking Therapeutics generating significant analyst enthusiasm. The biopharmaceutical company finds itself at the center of attention following Leerink Partners’ reaffirmation of their optimistic outlook, maintaining a $118 price target that suggests substantial growth potential from current trading levels near $36.27.

Positioning in a Expanding Market

The pharmaceutical sector’s race to develop effective weight-loss treatments has created a market opportunity measured in trillions of dollars. Currently, industry giants Eli Lilly and Novo Nordisk maintain dominant positions with their GLP-1 agonist therapies. Viking Therapeutics aims to disrupt this established dynamic with its investigational compound VK2735, a dual-acting agent that simultaneously targets both GLP-1 and GIP receptors.

Recent analyst assessments follow critical developmental progress. Patient enrollment has concluded for the Phase 2 trial evaluating an oral formulation, while preparatory work advances for Phase 3 studies of the subcutaneous version. With obesity treatment markets projected to reach $100 billion by 2030, market observers identify Viking as the most promising competitor to the current industry duopoly.

Diverging Perspectives: Analyst Optimism Meets Financial Reality

A noticeable gap exists between current valuation and future expectations. Sixteen market researchers currently monitor the company’s stock, collectively assigning a “Moderate Buy” consensus rating. Their average twelve-month price projection stands at $87.14, indicating approximately 140% upside potential.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

J.P. Morgan maintains a particularly favorable view with a “Buy” recommendation and $75 target, while Leerink Partners’ $118 projection represents the most bullish assessment. However, contrasting this analyst confidence, corporate insiders have disposed of shares valued at $3.93 million during the previous ninety days.

Financial Performance and Future Milestones

As a clinical-stage biotechnology enterprise, Viking Therapeutics continues to operate without commercial revenue. Third-quarter financial results revealed a per-share loss of $0.81, exceeding anticipated losses by $0.14. The company’s market capitalization of $4.10 billion, combined with institutional ownership representing 76% of outstanding shares, demonstrates that market valuation primarily reflects potential pipeline success rather than current financial performance.

Significant near-term developments await investors. Comprehensive data from oral VK2735 clinical trials and regulatory updates concerning the Phase 3 program are anticipated in early 2026. Until these catalysts materialize, the $36 price level remains technically significant for maintaining the stock’s chart structure.